Literature DB >> 2365090

Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis.

M S Saedi1, R Anand, W G Conroy, J Lindstrom.   

Abstract

The main immunogenic region (MIR) of the acetylcholine receptor (AChR) is the target for the majority of high-affinity autoantibodies produced in myasthenia gravis patients. Some monoclonal antibodies (mAbs) to the MIR bind specifically, but with low affinity, to synthetic AChR alpha subunit peptides with the sequence alpha 67-76. Studies of synthetic peptides suggest that amino acids alpha 68 and alpha 71 may be especially important to the antigenic structure of the MIR. We have studied the contribution of amino acids alpha 68 and alpha 71 to the antigenicity of the MIR on intact AChR by replacing alpha 68 (N) and alpha 71 (D) of Torpedo AChR alpha with alpha 68 (D) and alpha 71 (K) by site-directed mutagenesis, expressing the mutated transcripts in Xenopus oocytes along with wild-type Torpedo beta, gamma and delta subunits, and analyzing the expressed AChR for the binding of mAbs to the MIR. These mutations of the MIR greatly diminished binding of mAbs to the MIR. Thus, both alpha 68 and alpha 71 are critical to the antigenicity of the MIR in intact AChRs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365090     DOI: 10.1016/0014-5793(90)80286-r

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Paralytic zebrafish lacking acetylcholine receptors fail to localize rapsyn clusters to the synapse.

Authors:  F Ono; S Higashijima ; A Shcherbatko; J R Fetcho; P Brehm
Journal:  J Neurosci       Date:  2001-08-01       Impact factor: 6.167

2.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

3.  Detection of antibodies directed against the cytoplasmic region of the human acetylcholine receptor in sera from myasthenia gravis patients.

Authors:  S J Tzartos; M Remoundos
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 4.  Ligand-gated ion channels. Homology and diversity.

Authors:  V B Cockcroft; D J Osguthorpe; E A Barnard; A E Friday; G G Lunt
Journal:  Mol Neurobiol       Date:  1990 Fall-Winter       Impact factor: 5.590

Review 5.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 6.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 7.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

8.  Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity.

Authors:  Jie Luo; Palmer Taylor; Mario Losen; Marc H de Baets; G Diane Shelton; Jon Lindstrom
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

9.  Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains.

Authors:  Jon Lindstrom; Jie Luo; Alexander Kuryatov
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

10.  Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss.

Authors:  T Guyon; A Wakkach; S Poea; V Mouly; I Klingel-Schmitt; P Levasseur; D Beeson; O Asher; S Tzartos; S Berrih-Aknin
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.